April 18, 2024

Cybin Continues Advancement of Psilocybin Program in Major Depressive Disorder

PRISM Emerging Psychedelics Index company, Cybin, Inc (NYSE American: CYBN) has been granted an important patent in support of the company’s proprietary deuterated psilocybin analog program in Major Depressive Disorder (MDD). CYB003 is a new chemical entity (NCE) and has been granted FDA Breakthrough Therapy Designation for the adjunctive treatment of MDD. Cybin has successfully… [Read More]
April 18, 2024

Lipella Pharmaceuticals Brings Oncology Expertise to Advisory Board

Shares in biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) rose nearly 4.0% in intraday trading on Wednesday after the company announced it would expand its Scientific Advisory Board to include oncology expertise. Dr. Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the William Beaumont… [Read More]
April 17, 2024

PRISM Market Moves on Wednesday: United Airlines Outperforms, Mobileye Global Gains; Autodesk Drops on Missing 10K Filing

US equities are trading lower at midday on Wednesday after a mostly lower finish on Tuesday that saw the S&P 500, Nasdaq, and the Russell 2000’s third consecutive decline. Underperformers today are C&E, road/rail, MedTech, and semi caps, while airlines, industrial metals, managed care, investment banks, food/beverages, utilities, and credit cards are outperforming. Big tech… [Read More]
April 17, 2024

Auto Parts 4 Less Sees More on Revenue Growth and Forward Financial Progress

The e-commerce automotive parts retailer Auto Parts 4 Less Inc. (FLES) has announced significant growth in revenues. The company’s unaudited revenues grew from $48,573 to $102,409 between January and March, which is mostly attributed to its LiftKits4Less.com platform that the company reactivated five months ago after having taken a pause due to Covid. The company’s… [Read More]
April 17, 2024

Ferring Pharmaceuticals Initiates Three New Clinical Trials in Bladder Cancer

Privately-held specialty pharmaceutical group, Ferring Pharmaceuticals, has initiated three new US-based clinical trials evaluating ADSTILADRIN in patients with non-muscle invasive bladder cancer (NMIBC), and plans to expand select clinical trials outside of the US later in 2024. ADSTILADRIN was approved by the FDA in December 2022 for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC… [Read More]
April 17, 2024

Ethics Review Approval for Lexaria’s GLP-1 Study

Lexaria Bioscience (Nasdaq: LEXX) has received approval from an independent third-party ethics review board for its human pilot study #2 investigating GLP-1 drugs in combination with Lexaria’s DehydraTECH technology. Lexaria will begin recruiting subjects for the study immediately, and expects to dose the first patient within 30 days. The company’s share price rose more than… [Read More]
April 16, 2024

Oncocyte Partners with Bio-Rad to Commercialize Solid Organ Transplantation Monitoring Test

Precision diagnostics company, Oncocyte Corporation (Nasdaq: OCX), has entered a strategic partnership with Bio-Rad Laboratories (NYSE: BIO), for the commercialization of its GraftAssure™ assay, a blood-based solid organ transplantation monitoring test powered by Droplet Digital™ PCR (ddPCR™). The new Research Use Only product is designed to detect signs of graft damage and is expected to… [Read More]